As of June 5, 2025, Inhibikase Therapeutics Inc (IKT) reports a Net Margin of -7304.75%.
Net Margin shows the share of revenue that becomes profit after all costs, reflecting overall profitability.
Historical Trend of Inhibikase Therapeutics Inc's Net Margin
Over recent years, Inhibikase Therapeutics Inc's Net Margin has shown a stable trend. The table below summarizes the historical values:
| Date | Net Margin |
|---|---|
| 2024-12-31 | -7304.75% |
| 2023-12-31 | -7304.75% |
| 2022-12-31 | -15041.67% |
| 2021-12-31 | -477.10% |
| 2020-12-31 | -407.14% |
This fluctuation highlights how Inhibikase Therapeutics Inc manages its overall profitability and cost control over time.
Comparing Inhibikase Therapeutics Inc's Net Margin to Peers
To better understand Inhibikase Therapeutics Inc's position, it's useful to compare its Net Margin against industry peers. Below are selected comparisons:
| Company | Net Margin |
|---|---|
| Inhibikase Therapeutics Inc (IKT) | -7304.75% |
| Enzon Pharmaceuticals Inc (ENZN) | 2992.31% |
| Regeneron Pharmaceuticals Inc (REGN) | 31.07% |
| Amgen Inc (AMGN) | 12.24% |
| Abbvie Inc (ABBV) | 7.59% |
| Gilead Sciences Inc (GILD) | 1.67% |
Compared to its competitors, Inhibikase Therapeutics Inc's Net Margin is about average compared to peers, reflecting typical industry profitability.